Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 12/20 | 0.39 |
| ▸ | F2 | P00734 | 6/20 | 0.39 |
| ▸ | PLAT | P00750 | 6/20 | 0.39 |
| ▸ | PLG | P00747 | 6/20 | 0.31 |
| ▸ | KLK8 | O60259 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | KLK2 | P20151 | 1/20 | 0.31 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13736162 | 0.91 | PLAU (0.39) | PLAUF2PLATPLGKLK8 | |
| SCHEMBL13736718 | 0.90 | PLAU (0.34) | PLAUF2PLATPLGKLK8 | |
| SCHEMBL13737941 | 0.90 | PLAU (0.34) | PLAUF2PLATPLGKLK8 | |
| SCHEMBL13736055 | 0.86 | PLAU (0.40) | PLAUF2PLATPLGKLK8 | |
| SCHEMBL15522505 | 0.82 | PLAU (0.36) | PLAUF2PLATPLGANPEP | |
| SCHEMBL13736751 | 0.81 | PLAU (0.41) | PLAUF2PLATPLGKLK8 | |
| SCHEMBL13738041 | 0.81 | PLAU (0.37) | PLAUF2PLATPLGANPEP | |
| SCHEMBL13737828 | 0.81 | PLAU (0.34) | PLAUF2PLATPLGKLK8 | |
| Trifluoroacetic Acid SCHEMBL13738336 | 0.79 | PLAU (0.60) | PLAUF2PLATPLGKLK8 | |
| SCHEMBL13736386 | 0.76 | PLAU (0.35) | PLAUF2PLATPLGKLK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| EP-2707034-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | Universiteit Antwerpen (BE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | PLAU 1/4885F2 165/4885PLAT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.